Combination Of Bispecific Antibodies Enable Targeted TNFRSF Agonism and Effective Antitumor Activity.
4-1BB is an inducible costimulatory molecule that requires receptor clustering to boost anti-cancer immune response. However, the clinical development of monoclonal antibodies targeting 4-1BB has been constrained by toxicities driven by systemic activation. To address this, bispecific antibodies (bsAbs) have been devel...